Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 21, 2026

Intuitive Announces Innovations to Advance Quintuple Aim

View original at globenewswire.com
Intuitive Announces Innovations to Advance Quintuple Aim SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced several recent and upcoming innovations, including enhancements across…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Product quality, safety and reliability are of utmost importance to customers as they increasingly rely on Intuitive's products to serve millions of patients globally.

    60% confidence
  • Intuitive is guided by a commitment to helping customers achieve the Quintuple Aim: improving patient care and outcomes, optimizing surgeon and care team experience, and expanding access to minimally invasive care while lowering the total cost of care.

    60% confidence
  • In 2027, Intuitive anticipates that the number of uses on certain core instruments will again increase, reducing per-procedure costs for da Vinci surgery and supporting the Quintuple Aim.

    60% confidence
  • When da Vinci 5 was introduced with 10,000 times the computing power of Xi, Intuitive committed to enabling the ongoing integration of new functions, capabilities, indications, and instrumentation on a regular cadence.

    60% confidence
  • Instrument encryption enhancements are currently in development and are neither approved/cleared nor available for sale.

    60% confidence
  • Force Feedback is expected to play a central role in advancing augmented dexterity and automated instrument control.

    60% confidence
  • Telepresence enhancements should transform learning and surgeon education around the world to unlock Intuitive's global network of more than 101,000 da Vinci-trained surgeons.

    60% confidence
  • The dV5 Complete Care plan guarantees 98% uptime and is currently exceeding 99% actual uptime.

    60% confidence
  • More than 1,400 da Vinci 5 systems have been installed globally, with more than 380,000 procedures performed by more than 12,800 surgeons in 10 countries as of Q1 2026.

    60% confidence
  • Da Vinci 5 is the most integrated and future-ready platform, designed to continue transforming surgery globally while expanding surgeon autonomy.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com